The prompt and efficient identification of targeted inhibitors against unscrupulous pathogenic viruses holds promise for preventing epidemic disease outbreaks. Herein, a comprehensive multichannel screening method (multiple docking cross-validation, molecular dynamics simulation, and density functional theory calculation) integrated with bioactivity identification is rationally established using sugar-based natural ligand libraries to target tobacco mosaic virus (TMV) capsid proteins. Encouragingly, compounds A0 (K = 0.14 μM) and A4 (K = 1.43 μM) were evaluated to have excellent binding capacities to TMV capsid protein, evidently exceeding that of viricide Ningnanmycin (K = 3.47 μM) by 24.8 and 2.4-folds. Moreover, A0 and A4 significantly down-regulated the expression of capsid proteins at the transcriptional level, effectively blocking the biosynthesis and assembly of TMV in tobacco. Additionally, bioactivity evaluation illustrated that the anti-TMV curative effects of A0 (EC = 310.9 μg/mL) and A4 (EC = 371.2 μg/mL) were comparable to Ningnanmycin (EC = 343.8 μg/mL). Considering the availability, cost and synthesis difficulty of precursors, the more affordable A4 is reckoned to be a promising candidate for capsid protein inhibitors and warrants further exploration in follow-up studies. Current findings highlight that this state-of-the-art virtual strategy, integrated with bioactivity validation, facilitates the discovery of targeted candidates to combat pathogenic viruses.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijbiomac.2025.140075 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!